Neratinib plus dasatinib has pre-clinical efficacy against HER2-positive breast cancer. (October 2022) - Conlon, N.; Roche, S.; O'Neill, F.; Meiller, J.; Browne, A.; Breen, L.; O'Driscoll, L.; Cremona, M.; Hennessy, B.; Crown, J.; Collins, D.